Pfizer had ended its clinical trials for COVID-19 vaccine with 95% efficacy.
Pfizer Inc. on Wednesday said that the final results from the late-stage trial of its COVID-19 vaccine show it was 95% effective
Also, Pfizer said that it had the required two months of safety data and will apply for an emergency use authorization (EUA) in the United States within days.
According to Pfizer, the efficacy of the said vaccine that was jointly developed with German partner BioNTech SE was consistent across age and ethnicity demographics, adding that there were no major side effects
Efficacy in adults over 65 years of age, who were at particular risk from coronavirus disease, was over 94%.
The final analysis came just a week after initial results from the clinical trial showed that the COVID-19 vaccine was more than 90% effective.
Moderna Inc. released the preliminary data for its COVID-19 vaccine on Monday and it showed similar effectiveness.
The better-than-expected data from the two COVID-19 vaccines — both developed with new technology known as “messenger RNA (mRNA)” — had raised hopes for an end to a resurgent coronavirus pandemic that had killed over 1.3 million people globally and caused great damage upon economies and daily life.
However, it would be months before large-scale rollouts start while some groups — including healthcare workers — would be prioritized in the United States for COVID-19 vaccinations this year.
The results came as the coronavirus disease was running rampant in the United States, Europe and elsewhere, placing a vast strain on healthcare systems with a record numbers of new infections and hospitalizations.